scholarly journals Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre

2021 ◽  
Vol 27 ◽  
pp. 43-52
Author(s):  
Arjun Nathan ◽  
Monty Fricker ◽  
Ruben De Groote ◽  
Amandeep Arora ◽  
Yuzhi Phuah ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Comparative Effectiveness ◽  
High Volume ◽  
Effectiveness Study ◽  
Robot Assisted ◽  
Tertiary Centre ◽  
Comparative Effectiveness Study

scholarly journals 283 Salvage Versus Primary Robot-Assisted Radical Prostatectomy: A Propensity-Matched Comparative Effectiveness Study from A High-Volume Tertiary Centre

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
A Nathan ◽  
M Fricker ◽  
R De Groote ◽  
A Arora ◽  
Y Phuah ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
High Volume ◽  
Patient Characteristics ◽  
Primary Treatment ◽  
Complication Rates ◽  
Robot Assisted ◽  
Oncological Outcomes ◽  
Tertiary Centre ◽  
Comparative Effectiveness Study ◽  
Primary Groups

Abstract Aim Salvage Robot-Assisted Radical Prostatectomy (sRARP) is a potential treatment option for locally recurrent Prostate Cancer after non-surgical primary treatment. There are minimal data comparing outcomes between propensity-matched salvage and primary Robot-Assisted Radical Prostatectomy (RARP). We compare perioperative, oncological, and functional outcomes of sRARP with primary RARP and between sRARP post-whole and focal gland therapy. Method 1:1 propensity-matched comparison of 146 sRARP with primary RARP from a cohort of 3,852 consecutive patients from a high-volume tertiary centre. Results There were no significant differences in patient characteristics between the salvage and primary RARP groups. Grade III-V Clavien-Dindo complication rates were 1.3% and 0% in the salvage and primary groups, respectively (p = 0.310). Median (IQR) follow-up was 16 (10,30) and 21 (13,33) months in the salvage and primary groups, respectively. BCR rates were 30.8% and 13.7% in the salvage and primary groups, respectively (p < 0.001). Pad-free continence rates were 79.1% and 85.4% at two years in the salvage and primary groups, respectively (p = 0.160). ED rates were 95.2% and 77.4% in the salvage and primary groups, respectively (p < 0.001). Comparing the whole gland and focal gland groups, BCR rates were 33.3% and 29.1%, respectively (p = 0.687), pad-free continence rates were 66% and 89.3%, respectively (p = 0.001), and ED rates were 98.3% and 93%, respectively (p = 0.145). Conclusions SRARP has similar perioperative but inferior oncological outcomes to primary RARP. Continence rates are similar to primary RARP, but potency is worse. Perioperative and oncological outcomes of sRARP after focal gland therapy are similar but continence outcomes are superior compared to sRARP after whole gland therapy.

scholarly journals Salvage versus primary robot-assisted radical prostatectomy: a propensity-matched comparative effectiveness study from a high-volume tertiary centre

2021 ◽  
Author(s):  
Arjun Nathan ◽  
Monty Fricker ◽  
Ruben De Groote ◽  
Amandeep Arora ◽  
Yuzhi Phuah ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
High Volume ◽  
Patient Characteristics ◽  
Primary Treatment ◽  
Complication Rates ◽  
Risk Propensity ◽  
Robot Assisted ◽  
Oncological Outcomes ◽  
Tertiary Centre ◽  
Primary Groups

Introduction Salvage Robot-Assisted Radical Prostatectomy (sRARP) is a potential treatment option for locally recurrent Prostate Cancer after non-surgical primary treatment. There are minimal data comparing outcomes between similar-risk, propensity-matched salvage and primary Robot-Assisted Radical Prostatectomy (RARP). We compare perioperative, oncological and functional outcomes of sRARP with primary RARP and between sRARP post-whole and focal gland therapy. Methods 1:1 propensity-matched comparison of 146 sRARP with primary RARP from a cohort of 3,852 consecutive patients from a high-volume tertiary centre. Results There were no significant differences in patient characteristics between the salvage and primary RARP groups. Grade III-V Clavien-Dindo complication rates were 1.3% and 0% in the salvage and primary groups (p=0.310). Median (IQR) follow-up was 16 (10, 30) and 21 (13, 33) months in the salvage and primary groups. BCR rates were 30.8% and 13.7% in the salvage and primary groups (p<0.001). Pad-free continence rates were 79.1% and 85.4% at two years in the salvage and primary groups (p=0.160). Erectile dysfunction was 95.2% and 77.4% in the salvage and primary groups (p<0.001). On comparison of whole and focal gland groups, biochemical recurrence was 33.3% and 29.1% (p=0.687), pad-free continence rates were 66% and 89.3% (p=0.001), and ED rates were 98.3% and 93% (p=0.145). Conclusions SRARP has similar perioperative but inferior oncological outcomes to primary RARP. Continence rates are similar to primary RARP, but potency is worse. Perioperative and oncological outcomes of sRARP after focal gland therapy are similar compared to after whole gland therapy but continence outcomes are superior.

scholarly journals Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Helgo Magnussen ◽  
◽  
Sarah Lucas ◽  
Therese Lapperre ◽  
Jennifer K. Quint ◽  
...  
Keyword(s):  
Primary Care ◽  
Triple Therapy ◽  
Comparative Effectiveness ◽  
Inhaled Corticosteroids ◽  
Blood Eosinophil ◽  
Research Database ◽  
Effectiveness Study ◽  
Increased Risk ◽  
Comparative Effectiveness Study ◽  
Oral Corticosteroids

Abstract Background Inhaled corticosteroids (ICS) are indicated for prevention of exacerbations in patients with COPD, but they are frequently overprescribed. ICS withdrawal has been recommended by international guidelines in order to prevent side effects in patients in whom ICS are not indicated. Method Observational comparative effectiveness study aimed to evaluate the effect of ICS withdrawal versus continuation of triple therapy (TT) in COPD patients in primary care. Data were obtained from the Optimum Patient Care Research Database (OPCRD) in the UK. Results A total of 1046 patients who withdrew ICS were matched 1:4 by time on TT to 4184 patients who continued with TT. Up to 76.1% of the total population had 0 or 1 exacerbation the previous year. After controlling for confounders, patients who discontinued ICS did not have an increased risk of moderate or severe exacerbations (adjusted HR: 1.04, 95% confidence interval (CI) 0.94–1.15; p = 0.441). However, rates of exacerbations managed in primary care (incidence rate ratio (IRR) 1.33, 95% CI 1.10–1.60; p = 0.003) or in hospital (IRR 1.72, 95% CI 1.03–2.86; p = 0.036) were higher in the cessation group. Unsuccessful ICS withdrawal was significantly and independently associated with more frequent courses of oral corticosteroids the previous year and with a blood eosinophil count ≥ 300 cells/μL. Conclusions In this primary care population of patients with COPD, composed mostly of infrequent exacerbators, discontinuation of ICS from TT was not associated with an increased risk of exacerbation; however, the subgroup of patients with more frequent courses of oral corticosteroids and high blood eosinophil counts should not be withdrawn from ICS. Trial registration European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS30851).

Sign in / Sign up

Export Citation Format

Share Document